AtriCure recently released its 10-Q report. The company develops and sells devices used in surgical ablation of cardiac tissue, left atrial appendage exclusion, and temporary pain control through nerve ablation. Its products are sold to medical centers in the U.S., Asia-Pacific and other international markets through direct sales teams and distributors, and the company is based in Mason, Ohio.
In Item 2, AtriCure said worldwide revenue for the six months ended June 30, 2026 rose to $294.9 million from $259.8 million a year earlier, an increase of $35.1 million, or 13.5%, and 12.6% on a constant-currency basis. For the second quarter, revenue increased 12.8% to $153.6 million from $136.1 million.
The company said the six-month gain was driven by accelerated adoption in pain management, appendage management and open ablation. In the quarter, U.S. revenue rose 13.6% to $125.6 million, while international revenue increased 9.6% to $28.0 million.
By product line in the second quarter, open ablation revenue increased 12.1% to $40.9 million, pain management rose 27.8% to $27.1 million, and appendage management climbed 14.4% to $51.6 million. Minimally invasive ablation fell 23.1% to $6.0 million, which the company attributed to a continued reduction in hybrid procedures as physicians adopt PFA catheters.
Gross profit in the quarter was $118.6 million, up from $101.5 million, and gross margin improved to 77.2% from 74.5%. For the first half, gross profit reached $227.9 million, compared with $194.1 million a year earlier.
Research and development expense declined 9.8% in the quarter to $26.4 million, mainly because a $5.0 million pulsed-field ablation co-development milestone payment was made in the second quarter of 2025. That decrease was partly offset by $847,000 of higher product development spending, $801,000 of higher regulatory filing and submission costs, and $498,000 of higher personnel costs.
Selling, general and administrative expense rose 5.3% in the quarter to $82.6 million, led by $2.2 million of higher personnel costs, $1.4 million of higher marketing and training costs, and $579,000 of higher IT expenses. Operating income was $9.7 million in the quarter, compared with a loss of $6.2 million a year earlier, and net income was $9.0 million versus a net loss of $6.2 million.
For the first six months, operating income was $10.2 million, compared with an operating loss of $12.1 million in the prior-year period. Following these announcements, the company's shares moved 5.55%, and are now trading at a price of $36.985. Check out the company's full 10-Q submission here.
